CTOs on the Move

Verge Genomics

www.vergegenomics.com

 
We are pioneering a better drug discovery process using systems biology to improve the lives of people with neurodegenerative disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Verge Genomics raised $32M on 07/17/2018

Similar Companies

Esker Therapeutics

We are a precision medicines company looking to eliminate the “all comer” approach that is seen with today`s treatments for people with autoimmune disease. We are leveraging a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease.

Apeel Sciences

Apeel Sciences creates products from natural plant extracts that allow growers to reduce reliance on pesticides, increase produce quality, and provide superior shelf life without refrigeration.

Matthew Gibbs

CipherBio@SVB: Search life science fundraising news and data to discover innovative companies backed by venture investors https://t.co/mmTCuwa0Mc

Endobiologics

Endobiologics is a Missoula, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Insitro

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients. At insitro, we are rethinking the entire drug discovery process, from the perspective of machine learning, human genetics, and high-throughput, quantitative biology. Over the past five decades, we have seen the development of new medicines becoming increasingly more difficult and expensive, leaving many patients with significant unmet need. We`re embarking on a new approach to drug development – one that leverages machine learning and unique in vitro strategies for modeling disease state and designing new therapeutic interventions. We aim to eliminate key bottlenecks in traditional drug discovery, so we can help more people sooner and at a much lower cost to the patient and the healthcare industry. We believe that by harnessing the power of technology to interrogate and measure human biology, we can have a major impact on many diseases. We invest heavily in cutting edge bioengineering technologies to enable the construction of large-scale, high-quality data sets that are designed specifically to drive machine learning methods. Our first application is to use human genetics, functional genomics, and machine learning to build a new generation of in vitro human cell-derived disease models whose response to perturbation is designed to be predictive of human clinical outcomes.